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The eye lens exposure among 16 technicians in two nuclear medicine departments at university hospitals in Finland was
investigated by measuring the operational quantity Hp(3) using EYE-D dosemeters. For all workers, the annual mean Hp(3)
was estimated to be 1.1 mSv (max. 3.9 mSv). The relation between Hp(3) to routinely monitored personal dose equivalent
Hp(10) was clearly correlated. Considering individual dose measurement periods (2–4 weeks), the Hp(3)/Hp(10) ratio was 0.7
(Pearson’s coefficient r = 0.90, p < 0.001, variation of ratio 0.1–2.3). The variation decreased considerably with increasing
Hp(10) (σ 2 = 0.04 vs. 0.43 for Hp(10) > 0.1 mSv vs. < 0.1 mSv, respectively), i.e. higher Hp(10) predicts Hp(3) more reliably.
Moreover, annual Hp(10) data from national dose register during 2009–2018 were used to derive the annual Hp(3) applying
the Hp(3)/Hp(10) ratio. The data from Finnish nuclear medicine departments imply that routine measurements of Hp(3) among
nuclear medicine technicians are not justified.
INTRODUCTION
The allowed annual equivalent dose to the lens of the
eye for occupational exposure has been prominently
reduced from 150 mSv to a mean value of 20 mSv
obtained over a period of 5 years and with no single
year exceeding 50 mSv. The transition is based on
epidemiological studies showing that the eye lens is
more sensitive to radiation than previously consid-
ered and that the threshold for eye lens opacities
is much lower or that there may not be a thresh-
old at all. Dose response in cataract formation was
observed among atom bomb survivors investigated
55 years post exposure(1). Examinations of lens opac-
ities due to fractionated and protracted irradiation
among Chernobyl cleanup workers 12 and 14 years
after exposure suggested that there is an accumu-
lated dose threshold of 0.35 Sv for certain types of
cataract and opacity. Further, studies on radiological
technologists(2, 3) and interventional cardiologists(4)
implied that cataracts may occur after exposure to
much lower doses than was earlier comprehended.
Based on these, and a large number of other inves-
tigations, the International Commission on Radio-
logical Protection (ICRP) concluded that the life-
time dose threshold for induction of cataracts needs
to be lowered to an absorbed dose of 0.5 Gy by
acute or protracted exposure(5). The previously rec-
ommended thresholds were 2–10 Gy for single brief
exposures and above 8 Gy for protracted exposures(6).
The ICRP 2012 states that ‘the new recommended
equivalent dose limit for occupational exposure of the
lens of the eye is based on prevention of radiogenic
cataracts’. The new ICRP recommendation has been
adopted by the European Union (EU) in the Direc-
tive 2013/59/EURATOM(7) and by the International
Atomic Energy Agency (IAEA), in the new interna-
tional basic safety standards publication(8). Subse-
quently, many states, Finland included, have imple-
mented the equivalent dose limits for the lens of the
eye from the new basic safety standards into national
legislation (Finnish Radiation Act 859/2018, 2018,
Finnish Government Decree on Ionising Radiation
1034/2018, 2018). According to ICRU 51(9), opera-
tional quantities (personal dose equivalents) can be
used as surrogates for protection quantities. There-
fore, in the case of the lens of the eye, Hp(3) (i.e.
personal dose equivalent to the lens of the eye) can
be used to estimate the protection quantity equivalent
dose to the lens of the eye.
In nuclear medicine, the work involves tasks with
close contact to a wide range of radionuclides that
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Of these, gamma radiation and sufficiently high
energy beta radiation may penetrate to the eye lens,
and potentially induce high doses and radiation
effects to the workers. The recent epidemiological
evidence demonstrating the radiosensitive character-
istics of the lens of the eye and the new legislation for
annual limits for the lens have led to increased aware-
ness of occupational eye lens exposure, including the
exposure among nuclear medicine workers. Dabin
et al.(10) monitored Hp(3) for 45 nuclear medicine
staff members and estimated the annual dose to
range between 0.6 and 9.3 mSv. Other investigations
have reported annual Hp(3) of less than 2 mSv for
workers at a PET radiopharmaceutical facility(11)
and also a PET/CT centre(12). One of the objectives
of this study was to measure Hp(3) among workers
in two nuclear medicine units in Finland. Further,
instead of measuring Hp(3), the possibility to estimate
Hp(3) using other operational quantities, particularly
Hp(10), was investigated. Also, applying the measured
Hp(3)/Hp(10) ratios and records from dose register,
annual Hp(3) was estimated for technicians who had
been working in nuclear medicine units in Finland
during a period of 10 years. To our knowledge, the
Hp(3)/Hp(10) ratio approach utilising dose register
Hp(10) data for estimation of Hp(3) levels for




Thermoluminescent detectors (MCP-N, Radcard,
Poland) inserted into EYE-DTM dosemeters (Rad-
card) were used for measuring Hp(3). The decision
was made to perform calibration with 137Cs, taking
into consideration the range of photon energy of
the radionuclides used in nuclear medicine and that
these rarely emit beta particles or positrons with a
range larger than 3 mm in polyamide, i.e. the capsule
material in the EYE-D dosemeter. The detectors were
calibrated against 137Cs at the secondary standard
dosimetry laboratory of Radiation and Nuclear
Safety Authority (STUK). All detector readings
were performed with a TOLEDO 654 reader (Vinten
Instruments Limited, UK). A linear response for 10
doses from 100 μSv to up to 20 mSv was achieved
using slab phantom, and the results were verified
using the PMMA 20 cm x 20 cm cylinder phantom(13).
A blinded performance test was conducted showing
that the MCP-N detector in the eye dosemeter was
able to detect doses below 40 μSv.
Energy response of the eye dosemeters was tested
with the slab phantom using 10 x-ray ISO narrow
qualities (ISON 25 to ISON 250; ISO 4037-1, 1996)
with mean energy ranging from 20 to 208 keV and
showing a ratio of relative response (the response of
ISO N qualities with respect to 137Cs) between 0.8
and 1.2 resembling to a large extent the response with
the cylinder phantom performed by Bilski et al.(13).
Using the cylinder phantom, the energy response
was repeated with ISO N80, N120, N250 and 137Cs,
the results showing that the relative response for
these energies was within 3% of the response for the
slab phantom. Since the dosemeters were irradiated
from different directions in various work tasks at
the nuclear medicine units, the angle of incidence was
tested for ISO N80, N250 and 137Cs using the cylinder
phantom. The tested angles were 45◦ from both front
and reverse side of the EYE-D capsule and, also 90◦,
i.e. from the side of the capsule, and compared to
reference direction 0◦. The results showed that all
angles were well in line with the 0◦ response, except for
the 90◦ where an overresponse for the tested energies
was observed. For 662 keV gamma radiation, the
influence was of the order of 5% and for 65 keV
about 25% (data not shown).
Study participants and measurements at nuclear
medicine units
Clearance for conducting the investigation was
obtained from the respective hospital administra-
tions. Volunteers from two nuclear medicine units
participated in the study. Since person identification
was necessary for the retrieval of individual dose
register data (including dose values below national
recording threshold, i.e. 0.1 mSv for Hp(10)),
informed consent was requested from the study
participants. Individual data were coded, and the data
from dose register and in the study were processed
anonymously.
Hp(3) was measured among 7 and 9 technicians
at nuclear medicine units at two university hospitals
(UH1 and UH2), respectively. The dosemeter was
attached to the arm of personal eyewear in most cases
except for two persons who wore the dosemeter in a
head band at UH2. The participants were instructed
to place the dosemeter as near eye level as possible,
whereas no guidance was given about which side of
the head the EYE-D dosemeter should be located.
This decision was made since there was no predom-
inant angle or orientation of the handled sources
with respect to the eye dosemeter in any of the work
tasks. Measurement periods varied between 8 and 20
working days and were synchronised with the periods
of the official staff dosemeters for measuring per-
sonal dose equivalent Hp(10), i.e. each person wore
one eye dosemeter and one whole body dosemeter
during the measurement period. The seven partici-
pants at UH1 wore eye dosemeters during several
measurement periods resulting in 23 dose values. At
UH2, only one measurement period was conducted
for each participant. Out of 32 measurement peri-
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dosemeter and one broken dosemeter during the mea-
surement period. Background dose was monitored
for both Hp(3) and Hp(10) by placing dosemeters in
rest areas/locker rooms within the premises of the
nuclear medicine units. When not in use, all mea-
surement dosemeters were stored together with those
dosemeters allocated for background monitoring.
Work tasks included the following task entities:
operation of PET-CT and gamma camera/SPECT-
CT, preparation of radiopharmaceuticals, patient
preparation and care. The staff rotated in various
work tasks. Among UH1 participants, the aim was
to recruit technicians working especially with PET
tasks in order to potentially identify the highest
doses. The work tasks included handling of the
following nuclides: mainly 18F, 68Ga and 99mTc and
to a lesser extent 123I, 111In, 68Ge, 22Na and 57Co.
In 2017 at UH1, a total amount of 6550 patient
studies were conducted, excluding radionuclide
therapy treatments handled by doctors. Of these,
600 were 68Ga-Dotanoc or PSMA studies and 2050
18F-FDG-PET studies.
At UH2, the work tasks included handling of the
following nuclides: mainly 99mTc, 18F and 57Co and to
a lesser extent 68Ga, 131I and 123I. The total number of
patient studies in 2017 was 2640. Of these, 57 were
68Ga-PSMA studies and 817 18F-FDG-PET stud-
ies. At neither nuclear medicine department did the
workers use personal shields such as thyroid shield,
lead apron shield or lead glasses while working on
PET and gamma camera/SPECT-CT related tasks. At
both departments, an automatic injector was used for
18F-FDG injections. The participating personnel in
both nuclear medicine units were asked to keep record
on the approximate time spent at each work entity by
using a specific form.
Dosimetry
Estimation of Hp(3) received during one mea-
surement period was achieved by multiplying the
background-corrected TLD reading with the sen-
sitivity coefficient obtained from 137Cs calibration.
The annual dose for each worker was estimated by
firstly calculating an average daily dose based on the
measured values and length of measurement period
and thereafter multiplying this with an estimated
number of working days (220) during a year.
Whole body Hp(10) for the workers was mea-
sured using TLD-100 dosemeter. The dosemeters and
the measurement services were provided by approved
dosimetry service Doseco (Jyväskylä, Finland), and
the dose data were obtained from the national dose
register at STUK.
The uncertainty estimation included dosemeter
repeatability, individual sensitivity of dosemeter
(batch homogeneity), energy and angle responses as
well as dose calibration. Expanded uncertainty (k = 2)
of Hp(3) was estimated as ca. 18%, and for Hp(10),
this was estimated as 24% (Doseco).
Estimation of Hp(3) using Hp(10) obtained from
national dose register
To study the exposure of technicians working in
nuclear medicine on national scale, Hp(3) was
estimated from annual Hp(10) data gathered from
the national dose register. The ratio Hp(3)/Hp(10) =
0.7 estimated based on the TLD measurements was
applied to calculate Hp(3) from the dose register data.
The data covered all annual Hp(10) entries for
nuclear medicine technicians between the years 2009
and 2018, a total of 2813 entries. Since a 0.1 mSv
recording threshold for one measurement period of
Hp(10) is applied for the entries in the dose regis-
ter, the annual Hp(10) for category B workers was
reported as zero or slightly above zero. Thus, data
analysis was limited to the dose records of category
A workers, with 1721 register entries.
RESULTS AND DISCUSSION
Individual Hp(3) and Hp(10) measurements
Individual Hp(3) measured with the EYE-D doseme-
ters and Hp(10) from personal TLD-100 dosemeters
are plotted in Figure 1. The doses for single measure-
ment periods ranged from less than 10 to 250 μSv
for Hp(3) and to 300 μSv for Hp(10). The variation
in the measured doses reflects the range of work
tasks among participants and is also dependent on
differences in the length of measurement period. The
doses acquired at UH2 nuclear medicine unit are
clearly lower than doses at the UH1 unit. Table 1
shows that the content of work tasks between the
participating technicians in the two nuclear medicine
units was indeed dissimilar, the portion of recorded
working time allocated for PET related tasks being on
average 57% for UH1 technicians, whereas at UH2,
the technicians used on average 12% of their working
time for PET operations, excluding PET-TT imaging
of patients, including 18F-FDG automatic dispenser
loading, patient dose administrating, injections and
68Ga labeling and manual injections. The estimated
annual Hp(10) and Hp(3) and the number of measure-
ment periods for each technician are also presented
in Table 1. The annual doses were estimated with
the underlying assumption that the work tasks and
conditions would remain unchanged from what they
were during the measurement period. The highest
annual Hp(3) was 3.9 mSv for a technician who wore
the dosemeter only for a single measuring period
and whose work tasks consisted almost entirely of
PET work.
The relatively low annual Hp(3) observed in this
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Figure 1. Correlation of Hp(3) with respect to Hp(10). Each plotted value represents one dose measurement covering 8–
20 days of work at nuclear medicine units. Black symbols stand for UH1 and grey symbols for UH2. Error bars represent
measurement uncertainties (1 σ ).
the eye among technicians working at two nuclear
medicine units in Finland remain far below the annual
dose limits enforced in the new radiation legislation.
Similar results have been obtained in other stud-
ies on nuclear medicine departments, showing esti-
mated maximum annual Hp(3) of 3.7 mSv(14), about
2.5 mSv(15), 9.3 mSv(10), 4.5 mSv(16) and 8 mSv(17).
Considering the ICRP recommendations of dose lim-
its to the lens of the eye, these investigations imply that
the risk for radiogenic cataracts is comparatively low
among technicians conducting routine work tasks at
nuclear medicine departments.
Hp(3)/Hp(10) ratio
Figure 1 illustrates the relationship of Hp(3) with
Hp(10) and demonstrates a good Hp(3)/Hp(10)
correlation (linear regression equation slope of
0.70, Pearson’s coefficient r = 0.90, p < 0.001).
Excluding two measurements in which the doses
were practically zero, the individual Hp(3)/Hp(10)
ratios varied between 0.1 and 2.3. The vast majority
of the individual Hp(3)/Hp(10) ratios remained well
under unity, as demonstrated in Figure 2. It also
shows that all ratios above unity could be found
for Hp(10) below 0.1 mSv. This distinction was also
reflected in the ratios among the two nuclear medicine
units: the ratio for UH1 ranged between 0.1 and 1.0,
whereas at UH2 where the individual measurements
showed low doses in general, the ratios were between
0.4 and 2.2. Overall, there was a clear difference
in homogeneity of individual Hp(3)/Hp(10) ratios
in the group belonging to Hp(10) below 0.1 mSv
in comparison to the group above 0.1 mSv (σ 2
of 0.43 and 0.04, respectively), indicating that the
estimation of Hp(3) is more reliable at higher Hp(10)
values. Our results are in line with findings obtained
in other studies conducted on workers at nuclear
medicine departments. Dabin et al.(10) found a clear
correlation between Hp(10) measured at chest level
and Hp(3) among 45 staff members, although the
linear correlation was relatively poor (Pearson’s
coefficient r = 0.62). In other studies, the ratios were
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Table 1. Number of measurement periods, estimated annual Hp(3) and Hp(10) ± measurement uncertainty (1 σ ) and
approximated percentage of PET work for each nuclear medicine worker
Nuclear medicine
unit
Worker nr. Nr. of
measurement
periods
Hp(10) (mSv) Hp(3) (mSv) Portion of
PET-related work
tasks (%)
1 3 1.3 ± 0.2 0.4 ± 0.04 22
2 3 2.9 ± 0.3 2.2 ± 0.2 44
3 4 3.2 ± 0.4 1.8 ± 0.2 99
UH1 4 4 0.4 ± 0.05 0.05 ± 0.004 6
5 1 5.2 ± 0.6 3.9 ± 0.3 100
6 4 1.9 ± 0.2 1.2 ± 0.1 91
7 2 2.8 ± 0.3 2.1 ± 0.2 36∑
21 Mean 2.5 ± 0.3 1.7 ± 0.1 57
1 1 0.6 ± 0.1 0.6 ± 0.1 11
2 1 1.4 ± 0.2 0.6 ± 0.1 2
3 1 0.5 ± 0.1 0.7 ± 0.1 11
UH2 4 1 0.8 ± 0.1 1.0 ± 0.1 14
5 1 0.4 ± 0.04 0.8 ± 0.1 37
6 1 0.3 ± 0.04 0.4 ± 0.04 0
7 1 0.4 ± 0.05 0.6 ± 0.1 8
8 1 0.8 ± 0.1 1.0 ± 0.1 23
9 1 0.0 0.05 ± 0.004 0∑
9 Mean 0.6 ± 0.1 0.6 ± 0.1 12
Total 30 Mean 1.4 ± 0.2 1.1 ± 0.1
nurses(15), whereas an average Hp(3)/Hp(10) ratio of
0.55 was calculated based on 3-month measurements
among 19 workers(14). All these investigations give
strong implications to the use of Hp(10) as an
indicator of Hp(3) levels for nuclear medicine workers.
Further support comes from a study by Kopec
et al.(18) who found ratios of Hp(3)/Hp(10) between
0.7 and 1.1 among technical staff and nurses at one
scintigraphy and two PET-CT departments. They
also demonstrated the importance of appropriate
placement of the eye dosemeter for achieving correct
measurements. Walsh et al.(12) found Hp(3) values
measured by eye dosemeters to be within 50% of
the measured numeric Hp(10) values. The above
studies applied the MCP-N detector in the eye
dosemeter. Measurements performed with the TLD-
100 chip showed up to 200% higher Hp(3) values
in comparison to dose to the thorax(19). Several
factors may affect the magnitude of the Hp(3)/Hp(10)
ratio, one of them being the height of the person. In
interventional radiology, the ratio was shown to be
affected by the height of the radiologist so that the
ratio decreased with increasing height(20).
Angular and energy effects
In most cases in the present study, the EYE-D
dosemeters were worn attached to the personal
eyeglasses so that the black polyamide capsule
pointed outwards from the side of the head. The
measurements would ideally be performed with
eye dosemeters located on the forehead as close
to the eye as possible, e.g. placed on a head band.
Thus, the eyeglass attachment can be regarded as a
limitation of the study. While turning the head in
relation to the irradiation source, irradiation from
the front of the EYE-D capsule, from the side and
also from the back was enabled. Gamma radiation
emitted by typical nuclear medicine radionuclides
covers the energy range of about 0.1–0.66 MeV.
Angular tests covering this energy range indicated
that attaching the dosemeter to eyeglasses so that
they are irradiated from the side induces larger
uncertainties to dose estimate than irradiation to
the front of the EYE-D. However, the overresponse
lies well within the limits for angular response of
0.67–1.67(21), although these limits are only given
for maximum of 60◦ angle. The data also indicate
that the overresponse for irradiation from the side
increases with decreasing energy. Although the
attachment of the dosemeter was not ideal, the
overall assessment is that irrespective of the angle
of the eye dosemeter with respect to source, and with
energies covering typical nuclear medicine nuclides, a
relatively uniform response in the EYE-D dosimetry
is induced. Attaching the dosemeter to personal
eyewear naturally rules out the possibility to monitor
persons not wearing glasses. It should be also kept
in mind that different eyewear models and materials













ospital user on 17 N
ovem
ber 2020
Hp(3) AMONG NUCLEAR MEDICINE STAFF
Figure 2. Ratio Hp(3)/Hp(10) with respect to Hp(10). Error bars represent combined measurement uncertainty (1 σ ) from
both dose qualities.
Many of the radionuclides handled at the nuclear
medicine departments are beta emitters, and electrons
and positrons with energies of less than ca. 700 keV
are absorbed by the 3 mm polyamide capsule on
the EYE-D as illustrated by Szermerski et al.(22).
The study pointed out that betas from 131I and
positrons from 18F are fully attenuated, whereas
electrons and positrons with higher energies, e.g.
from 90Y and 68Ga, respectively, are penetrating the
polyamide layer and thus contributing to the dose.
Also, it was shown that the polyamide layer and
the detector together form a 4.6 mm thick layer of
tissue-equivalent material, i.e. much thicker than the
3 mm in the definition of Hp(3). Szumska et al.(23)
investigated the MCP-N detector for beta emitters
32P, 42K and 90Sr/90Y and showed that there is an
increasing response for the detector with increasing
energy of beta emitters.
Bruchmann et al.(24) have studied the influence
of protective eyewear on Hp(3) by exposure of head
phantoms with radionuclides commonly used in
nuclear medicine and that were emitting gamma
and/or beta/positron radiation. They found that
the attenuation effect for Hp(3) of both ordinary
laboratory glasses and leaded protective glasses
was highest at exposure to 90Y (factor < 0.1). The
attenuation factor for lead glasses was approximately
0.3, 0.9, 0.5 and 0.8 for 99mTc, 18F, 68Ga and 131I,
respectively, whereas the laboratory glasses were
much less protective. In interventional radiology
where lead glasses are often used by the interven-
tionist, the positioning of the eye dosemeter has a
substantial impact on the ratio between the measured
Hp(3) and actual eye lens equivalent dose(25). No
leaded eyewear was used in our study and the energy
spectra and the homogeneity of the radiation fields
within radiology diverge considerably in comparison
to those encountered in nuclear medicine. However, it
should be kept in mind that although the protection
quantity equivalent dose can be replaced by Hp(3) for
monitoring purposes, there may be differences in the
magnitude of these two quantities.
Hp(3) calculated from dose register data
Based on national dose register data for category A
technicians working in nuclear medicine, Figures 3
and 4 show respective boxplots of annual Hp(10)
and the ratio-derived Hp(3) values between 2009 and
2018. During the 10 year time span, the annual Hp(10)
on national level was on average 0.41 mSv and the
mean of the derived Hp(3) 0.28 mSv, also displayed
in Figures 3 and 4. The figures also show maximum
values for each year and during the 10-year period,
the highest Hp(10) was 4.6 ± 0.6 mSv and the derived-
Hp(3) 3.2 ± 1.2 mSv. The effect of possible non-
compliance to wearing personal dosemeters was not
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Figure 3. Statistics of measured Hp(10) values from the national dose register between 2009 and 2018. Boxes: upper
edge = 75th percentile, centre line = median. Whiskers = 1.5 interquartile ranges. Solid line: average, dotted line with error
bars = maximum Hp(10) values ± measurement uncertainty (1 σ ).
Figure 4. Statistics of Hp(3) estimates obtained by applying the regression model from Figure 1 to Hp(10) records from
national dose register. Boxes: upper edge = 75th percentile, centre line = median. Whiskers = 1.5 interquartile ranges. Solid
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the results derived based on the dose register data.
Compared to the average annual Hp(3) doses in the
overall national cohort, much higher average annual
Hp(3) dose (1.1 mSv, Table 1) was measured among
the 16 technicians participated in the study. This was
due to recruitment of technicians working particu-
larly with PET-related tasks where high doses are
potentially identified. The conclusion of the above is
that for nuclear medicine workers, the annual equiva-
lent dose levels would very unlikely reach the allowed
dose limit.
CONCLUSIONS
The results of this study, performed for technicians
at two nuclear medicine departments, indicate that
Hp(3), considered as a surrogate for the protection
quantity equivalent dose to the lens of the eye, does
not rise anywhere near the mean value of 20 mSv
over a five-year period. Good correlation between
the two operational quantities suggests that the ratio
Hp(3)/Hp(10) is a good candidate for estimation of
Hp(3) from Hp(10) among nuclear medicine work-
ers. Based on 10 years of Hp(10) data from nuclear
medicine technicians in Finland, the ratio-estimated
annual Hp(3) doses were shown to stay well below
the 20 mSv annual limit also long-term. Taking into
account the potential role of Hp(10) for determining
dose to the lens of the eye, and the relatively low
dose level observed in this study, there is no clear
indication to recommend routine Hp(3) measurement
among technicians working in nuclear medicine imag-
ing departments.
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